177 related articles for article (PubMed ID: 24840555)
21. Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo.
Suspène R; Guétard D; Henry M; Sommer P; Wain-Hobson S; Vartanian JP
Proc Natl Acad Sci U S A; 2005 Jun; 102(23):8321-6. PubMed ID: 15919829
[TBL] [Abstract][Full Text] [Related]
22. Target cell-mediated editing of HIV-1 cDNA by APOBEC3 proteins in human macrophages.
Koning FA; Goujon C; Bauby H; Malim MH
J Virol; 2011 Dec; 85(24):13448-52. PubMed ID: 21957290
[TBL] [Abstract][Full Text] [Related]
23. Elucidation of the Complicated Scenario of Primate APOBEC3 Gene Evolution.
Uriu K; Kosugi Y; Suzuki N; Ito J; Sato K
J Virol; 2021 May; 95(12):. PubMed ID: 33789992
[TBL] [Abstract][Full Text] [Related]
24. An overview of cytidine deaminases.
Navaratnam N; Sarwar R
Int J Hematol; 2006 Apr; 83(3):195-200. PubMed ID: 16720547
[TBL] [Abstract][Full Text] [Related]
25. APOBEC mutation drives early-onset squamous cell carcinomas in recessive dystrophic epidermolysis bullosa.
Cho RJ; Alexandrov LB; den Breems NY; Atanasova VS; Farshchian M; Purdom E; Nguyen TN; Coarfa C; Rajapakshe K; Prisco M; Sahu J; Tassone P; Greenawalt EJ; Collisson EA; Wu W; Yao H; Su X; Guttmann-Gruber C; Hofbauer JP; Hashmi R; Fuentes I; Benz SC; Golovato J; Ehli EA; Davis CM; Davies GE; Covington KR; Murrell DF; Salas-Alanis JC; Palisson F; Bruckner AL; Robinson W; Has C; Bruckner-Tuderman L; Titeux M; Jonkman MF; Rashidghamat E; Lwin SM; Mellerio JE; McGrath JA; Bauer JW; Hovnanian A; Tsai KY; South AP
Sci Transl Med; 2018 Aug; 10(455):. PubMed ID: 30135250
[TBL] [Abstract][Full Text] [Related]
26. Hepatitis B: modern concepts in pathogenesis--APOBEC3 cytidine deaminases as effectors in innate immunity against the hepatitis B virus.
Bonvin M; Greeve J
Curr Opin Infect Dis; 2008 Jun; 21(3):298-303. PubMed ID: 18448976
[TBL] [Abstract][Full Text] [Related]
27. APOBEC3 proteins and genomic stability: the high cost of a good defense.
Narvaiza I; Landry S; Weitzman MD
Cell Cycle; 2012 Jan; 11(1):33-8. PubMed ID: 22157092
[TBL] [Abstract][Full Text] [Related]
28. Apobec 3F and apobec 3G have no inhibition and hypermutation effect on the human influenza A virus.
Wang GF; Lin SY; Zhang H; Gao YL; Li WZ; Xin G; Li KS
Acta Virol; 2008; 52(3):193-4. PubMed ID: 18999897
[No Abstract] [Full Text] [Related]
29. Somatic hypermutation of human mitochondrial and nuclear DNA by APOBEC3 cytidine deaminases, a pathway for DNA catabolism.
Suspène R; Aynaud MM; Guétard D; Henry M; Eckhoff G; Marchio A; Pineau P; Dejean A; Vartanian JP; Wain-Hobson S
Proc Natl Acad Sci U S A; 2011 Mar; 108(12):4858-63. PubMed ID: 21368204
[TBL] [Abstract][Full Text] [Related]
30. Catalytic activity of APOBEC3F is required for efficient restriction of Vif-deficient human immunodeficiency virus.
Albin JS; Brown WL; Harris RS
Virology; 2014 Feb; 450-451():49-54. PubMed ID: 24503066
[TBL] [Abstract][Full Text] [Related]
31. Differential inhibition of long interspersed element 1 by APOBEC3 does not correlate with high-molecular-mass-complex formation or P-body association.
Niewiadomska AM; Tian C; Tan L; Wang T; Sarkis PT; Yu XF
J Virol; 2007 Sep; 81(17):9577-83. PubMed ID: 17582006
[TBL] [Abstract][Full Text] [Related]
32. The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3H.
Binka M; Ooms M; Steward M; Simon V
J Virol; 2012 Jan; 86(1):49-59. PubMed ID: 22013041
[TBL] [Abstract][Full Text] [Related]
33. Characterization of APOBEC3 variation in a population of HIV-1 infected individuals in northern South Africa.
Matume ND; Tebit DM; Gray LR; Turner SD; Rekosh D; Bessong PO; Hammarskjöld ML
BMC Med Genet; 2019 Jan; 20(1):21. PubMed ID: 30660178
[TBL] [Abstract][Full Text] [Related]
34. Antiviral potency of APOBEC proteins does not correlate with cytidine deamination.
Bishop KN; Holmes RK; Malim MH
J Virol; 2006 Sep; 80(17):8450-8. PubMed ID: 16912295
[TBL] [Abstract][Full Text] [Related]
35. Restriction by APOBEC3 proteins of endogenous retroviruses with an extracellular life cycle: ex vivo effects and in vivo "traces" on the murine IAPE and human HERV-K elements.
Esnault C; Priet S; Ribet D; Heidmann O; Heidmann T
Retrovirology; 2008 Aug; 5():75. PubMed ID: 18702815
[TBL] [Abstract][Full Text] [Related]
36. A conflict of interest: the evolutionary arms race between mammalian APOBEC3 and lentiviral Vif.
Nakano Y; Aso H; Soper A; Yamada E; Moriwaki M; Juarez-Fernandez G; Koyanagi Y; Sato K
Retrovirology; 2017 May; 14(1):31. PubMed ID: 28482907
[TBL] [Abstract][Full Text] [Related]
37. Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets.
Koning FA; Newman EN; Kim EY; Kunstman KJ; Wolinsky SM; Malim MH
J Virol; 2009 Sep; 83(18):9474-85. PubMed ID: 19587057
[TBL] [Abstract][Full Text] [Related]
38. Whole-genome sequencing reveals activation-induced cytidine deaminase signatures during indolent chronic lymphocytic leukaemia evolution.
Kasar S; Kim J; Improgo R; Tiao G; Polak P; Haradhvala N; Lawrence MS; Kiezun A; Fernandes SM; Bahl S; Sougnez C; Gabriel S; Lander ES; Kim HT; Getz G; Brown JR
Nat Commun; 2015 Dec; 6():8866. PubMed ID: 26638776
[TBL] [Abstract][Full Text] [Related]
39. DNA mismatch repair promotes APOBEC3-mediated diffuse hypermutation in human cancers.
Mas-Ponte D; Supek F
Nat Genet; 2020 Sep; 52(9):958-968. PubMed ID: 32747826
[TBL] [Abstract][Full Text] [Related]
40. Integration of Mutational Signature Analysis with 3D Chromatin Data Unveils Differential AID-Related Mutagenesis in Indolent Lymphomas.
Sepulveda-Yanez JH; Alvarez-Saravia D; Fernandez-Goycoolea J; Aldridge J; van Bergen CAM; Posthuma W; Uribe-Paredes R; Veelken H; Navarrete MA
Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884820
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
